In a placebo-controlled study, TOBI PODHALER significantly improved lung function1,2

EVOLVE: Evaluate Tobramycin inhaled dry powder efficacy Versus placebo in cystic fibrosis patients.
*Each cycle consisted of 28 days on treatment followed by 28 days off treatment.1
Mean absolute changes in FEV1% predicted: TOBI PODHALER: +6.38%; placebo: -0.52%. Difference: 6.90% (95% CI: 2.40, 11.40).
EVOLVE was a 24-week, randomized, double-blind (during Cycle 1) trial in patients aged 6 to 21 years with CF, Pa and FEV1 ≥25% and ≤80% predicted at screening. The first cycle was double-blind and placebo-controlled with eligible patients randomized 1:1 to TOBI PODHALER (four 28-mg capsules twice daily) or placebo. For Cycles 2 and 3, patients who were initially randomized to placebo received TOBI PODHALER. Of the 79 patients included in the prespecified interim analysis, 18 were excluded due to a failure to meet spirometry quality review criteria, which resulted in a total of 61 patients included in the primary analysis.1,2
After Cycle 1, patients who switched from placebo to TOBI PODHALER showed improvement in their lung function2

Error bars represent mean relative change (95% CI).1

CF: Cystic fibrosis; CI: Confidence interval; FEV1: Forced expiratory volume in 1 second; Pa: Pseudomonas aeruginosa.
Improvements in lung function were achieved during the subsequent cycles of treatment with TOBI PODHALER, although the magnitude of improvement was reduced.1
In a secondary analysis, TOBI PODHALER patients experienced fewer respiratory-related hospitalizations and needed less intravenous antipseudomonal antibiotics vs placebo1,2
15% fewer patients needed IV antipseudomonal antibiotics1
8.7% in the TOBI PODHALER treatment group vs 10.2% in the placebo group
Secondary endpoint in EVOLVE (Study 2, Cycle 1)
64% reduction in the percentage of patients with respiratory-related hospitalizations1
4.4% (n=2) in the TOBI PODHALER treatment group vs 12.2% (n=6) in the placebo group
Secondary endpoint in EVOLVE (Study 2, Cycle 1)
EDIT Study
Lung function in patients treated with TOBI PODHALER vs placebo was also evaluated in a separate 8-week study1

Results not statistically significant.1
Mean absolute change in FEV1% predicted was 4.86% for TOBI PODHALER and 0.48% for placebo, with a difference of 4.38% (95% CI: −1.17, 9.94).1
EDIT Study Design
  • EDIT was an 8-week, randomized, double-blind, placebo-controlled study in patients aged 6 to 21 years with CF, and FEV1 ≥25% and ≥80% predicted at screening
  • Patients with any use of inhaled antipseudomonal antibiotics within 4 months prior to screening were excluded1
  • Eligible patients were randomized 1:1 to receive TOBI PODHALER 1 time per day (112 mg; 4×28 mg capsules twice daily; n=32) or placebo (n=30) for one cycle (28 days on treatment and 28 days off treatment)1
  • The EDIT Study was underpowered due to an inability to recruit the prespecified number of TOBI-naïve patients into each arm3
EDIT: Establish tobramycin dry powder efficacy in cystic fibrosis.
 
Decreased susceptibility of Pa to tobramycin has been seen with use of TOBI PODHALER. The relationship between in vitro susceptibility test results and clinical outcome with TOBI PODHALER therapy is not clear. Occurrence of decreased susceptibility on treatment should be monitored, and treatment with an alternative therapy should be considered if clinical worsening is observed.1

REFERENCES

  1. TOBI Podhaler; PI; 04/2026.
  2. Konstan MW, Geller DE, Minic P, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol. 2011;46(3):230-238. doi:10.1002/pul.21356.
  3. Galeva I, Konstan MW, Higgins M, et al. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr Med Res Opin. 2013;29(8):947-956.